Office of the Registrar or Lobbying of BC

Menus

  • Menus

www.lobbyistsregistrar.bc.ca

  • www.lobbyistsregistrar.bc.ca

Designated Filer menu

  • Registry Search Tools
    • 12-Month Lobbying Activity Search
    • Advanced Registry Search
  • Reporting Tools
    • Recent Registrations
    • Recent Lobbying Activity Reports by Posted Date
    • Government Funding Report
    • Gifts to Public Office Holders Report
    • Listing of All Lobbyists and Senior Officers
    • Listing of Senior Public Officer Holders who are in Lobbying Activity Reports
    • Listing of Organizations Clients and their Direct Interests
  • Lobbying Statistics
    • Active Lobbyists and Registrations by Type
    • Ministries/Provincial Entities in Active Registrations
    • Ministries/Provincial Entities in Lobbying Activity Reports
    • Lobbying Activity Reports by Reporting Period
    • Subject Matter in Active Registrations
    • Subject Matter in Lobbying Activity Reports
    • Intended Outcomes in Active Registrations
    • Intended Outcomes in Lobbying Activity Reports
  • Help
    • LTA Guidance Documents
    • Using the Registry
    • Legislation
    • LTA Frequently Asked Questions
    • Contact Us
  • Sign In

You are here:

  1. Registry Dashboard

 

Subject matter details

Gilead Sciences Canada, Inc.


Registration: 32 of 32 (2025-08-26 to present)

Details Regarding the Identified Subject Matter
Specific Topics of Lobbying Communications Intended Outcomes Associated Subject Matters
Arranging meeting between an individual and a public office holder for purpose of lobbying. Meeting with British Columbia Centre for Excellence in HIV/AIDS (BCCfe) to discuss the provincial listing and reimbursement for HIV medications; meeting with Pharmaceutical Service Division (PSD) within the Ministry of Health to discuss the provincial listing and reimbursement of medications for the treatment of Viral Hepatitis, liver disease and rheumatoid arthritis; meeting with the BC Cancer Agency to discuss the provincial listing and reimbursement of oncology medications; meeting with BCCDC regarding public health policy related to viral hepatitis; and meeting with the Ministry of Health around health policy issue.
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
Health
Meeting with British Columbia Centre for Excellence in HIV/AIDS (BCCfe) to discuss the provincial listing and reimbursement for HIV medications; meeting with Pharmaceutical Service Division (PSD) within the Ministry of Health to discuss the provincial listing and reimbursement of medications for the treatment of Viral Hepatitis, liver disease and rheumatoid arthritis; meeting with the BC Cancer Agency to discuss the provincial listing and reimbursement of oncology medications; meeting with BCCDC regarding public health policy related to viral hepatitis, and COVID-19 and meeting with the Ministry of Health around health policy issues. Meetings with the Members of Legislative Assembly for topics above as well.
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
Health